莫达林 | 2856-74-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 莫达林
• 中文别名: 甲哗哌啶
• 英文名称: modaline
• 英文别名: 2-Methyl-3-piperidino-pyrazin；3-Piperidino-2-methyl-pyrazin；2-Piperidino-3-methylpyrazin；2-methyl-3-piperidin-1-yl-pyrazine；2-methyl-3-piperidin-1-ylpyrazine
• CAS: 2856-74-8
• 化学式: C₁₀H₁₅N₃
• 分子量: 177.249
• InChiKey: BJHCGMHPEKLROM-UHFFFAOYSA-N

物化性质

• 保留指数：
  1465;1473;1478;1495;1499;1503

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  29
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Pharmaceutical compositions containing at least one of haloperidol, imipramine or trifluoroperazine
  申请人：Bleiweiss, Eduardo Samuel

  公开号：EP0726073A2

  公开（公告）日：1996-08-14

  Pharmaceutical compounds for the treatment of patients which show symptoms of unspecified retarded maturity, such as Alzheimer's Disease and other diseases which have an origin in numeric anomalies, deletions or chromosomatic fragility. These compounds include specific non toxic quantities of, at least one of the following drugs: a) Haloperidol (4-(4-(4-Cholorophenol)-4-Hydroxy Piperidine)-1-(4-Fluorohenol)-1-Butanona; b) Imipramine (10,11-Dihydro-N,N-Dimetil-5H-Dibenz (b,f)- Flazepine-5-Propanamine; c) Trifluoperazine (10-(3-(4-Methyl-1-Piperazinil)-Propil)-2- Trifluoromethyl)-10H-Phenotiazine;

  用于治疗表现出不明成熟迟缓症状的病人的药物化合物，如老年痴呆症和其他源于数字异常、缺失或染色体脆弱的疾病。这些化合物包括以下至少一种药物的特定无毒量： a) Haloperidol（4-(4-(4-Cholorophenol)-4-Hydroxy Piperidine)-1-(4-Fluorohenol)-1-Butanona； b）丙咪嗪（10,11-二氢-N,N-二甲酰-5H-二苯并(b,f)-氟氮杂卓-5-丙胺； c) 三氟拉嗪（10-(3-(4-甲基-1-哌嗪基)-丙基)-2-三氟甲基）-10H-苯噻嗪；
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES
  申请人：UNIVERSITY OF FLORIDA

  公开号：EP0174342A1

  公开（公告）日：1986-03-19
• FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF
  申请人：Protarga Inc.

  公开号：EP1163011A2

  公开（公告）日：2001-12-19

表征谱图